NASDAQ:GRI

GRI Bio Q1 2026 Earnings Results & Report

GRI Bio logo
$1.12 0.00 (0.00%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$1.18 +0.06 (+5.27%)
As of 11/20/2026 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRI Bio missed analyst earnings expectations in its Q1 2026 results, released May 13, 2026. The company reported EPS of -$1.61 versus the -$1.6050 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

GRI Bio EPS Results

Actual EPS
-$1.61
Consensus EPS
-$1.6050
Beat/Miss
Missed by -$0.0050
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 5 quarters

GRI Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

GRI Bio's Q4 2026 earnings is estimated for Friday, January 29, 2027, based on past reporting schedules

GRI Bio Q1 2026 Earnings FAQ

GRI Bio (NASDAQ:GRI) reported earnings of -$1.61 per share for Q1 2026, missing the consensus estimate of -$1.6050. The report was announced on Wednesday, May 13, 2026.

GRI Bio's next earnings date is estimated for Friday, January 29, 2027. MarketBeat tracks confirmed and estimated earnings dates for GRI Bio on the company's earnings history page.

GRI Bio Earnings Headlines

FY2026 Earnings Estimate for GRI Bio Issued By HC Wainwright
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More GRI Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GRI Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRI Bio and other key companies, straight to your email.

About GRI Bio

GRI Bio (NASDAQ:GRI) is a clinical-stage biotechnology company developing therapies for inflammatory, fibrotic and autoimmune diseases. Its research focuses on invariant natural killer T (iNKT) cells, a type of immune cell involved in regulating inflammation and immune responses.

The company’s lead candidate, GRI-0621, is an oral investigational therapy being developed for idiopathic pulmonary fibrosis, a progressive lung disease. GRI Bio is also advancing other drug candidates that target iNKT-cell biology for potential use in immune-mediated conditions.

GRI Bio’s programs are in development, and its candidates have not been approved for commercial use. The company is based in the United States.

View GRI Bio Profile